Immunotherapeutic strategies in breast cancer: A clinical update

Immunotherapy has been incorporated into the standard of care for a wide range of malignancies. The study of tumor-infiltrating lymphocytes has emphasized the importance of the host antitumor immune response in the natural history of breast cancer. Recent clinical trials have used immunotherapeutic approaches to augment this response and improve outcomes for patients with breast cancer. Here, we review several current clinical trial data that indicate checkpoint blockade may mediate clinically significant responses.

Automated summary

Immunotherapy has become a standard treatment for various types of malignancies, including breast cancer, by enhancing the host antitumor immune response. Recent clinical trials have shown promising results in using checkpoint blockade to mediate clinically significant responses in breast cancer patients.